At a glance
ClinicalIndex Comparison RecordN/ACompleted· 991 enrolled
Drug / intervention
Pre-ART Oligonucleotide Assay (OLA)other
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Drug-resistance Testing in Kenya to Improve ART Suppression of HIV Replication
In Brief
A clinical study evaluating Pre-ART Oligonucleotide Assay (OLA) for HIV Positive. Completed, enrolled 991 participants across 2 sites.
Detailed Summary
The investigators propose to gauge improvements in the rate of durable suppression of viral replication by ART when OLA is used to guide clinical decisions at the PEPFAR Coptic Hope Center in Kenya, and to determine the cost-effectiveness of implementing this strategy at Coptic Hope Center.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Positive
CountriesKenya
CollaboratorsSeattle Children's Hospital, University of Nairobi
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2013
First PostedJul 2013
Primary CompletionDec 2016
Study CompletionFeb 2017
TodayJul 2026
First PostedJul 12, 2013
Enrollment StartMay 1, 2013
Primary CompletionDec 1, 2016
Study CompletionFeb 1, 2017
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 13.0 years ago
Interventions
Pre-ART Oligonucleotide Assay (OLA)other
Block randomization (1:1) to pre-ART OLA testing or OLA testing after 12mo on ART